Compugen, Roche Deal to ID Response Markers for RA Drugs May Lead to Dx | GenomeWeb
Compugen’s GeneVa technology will serve as the platform for Roche’s efforts to discover genetic variations linked to patient response to certain rheumatoid arthritis treatments.
 
Compugen, based in Tel Aviv, Israel, announced the co-discovery and license agreement on Dec. 20, saying the companies aim to develop an FDA-approved and CE Marked genetic test for best-responders.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.